REG - Ergomed plc - Award of Options by CEO to CFO and General Counsel <Origin Href="QuoteRef">ERGO.L</Origin>

ErgomedAnnouncement

30/11/2016 16:40

RNS Number : 5759Q
Ergomed plc
30 November 2016
PRESS RELEASE
FOR IMMEDIATE RELEASE
Award of options by Chief Executive Officer over personally owned shares to 
Chief Financial Officer and General Counsel
London UK 30 November 2016: Ergomed plc ("Ergomed" or the "Company", LSE: ERGO), a pharmaceutical services and drug development company, today announces that Dr Miroslav Reljanovi, founder and Chief Executive Officer of Ergomed, has granted options over 250,000 ordinary shares from his personal holding to Stephen Stamp, Chief Financal Officer and Sanja Juri, General Counsel as follows:
Name
No. of options
Exercise Price
Vesting
Resulting interest in options
Current shareholding in the Company
Stephen Stamp
100,000
0.01
50% 11 January 2017
50% 11 January 2018
500,000
200,000
Sanja Juri
150,000
0.01
50% 30 November 2016
50% 30 November 2017
300,000
NIL
The 250,000 ordinary shares over which Dr Reljanovi has granted options will remain in his personal holding until exercise. Dr Reljanovi is interested in 17,632,237 ordinary shares of the Company, representing 43.53% of the issued share capital.
- ENDS - 
Enquiries:
Ergomed plc
Tel: +44 (0) 1483 503205
Miroslav Reljanovic (Chief Executive Officer)

Stephen Stamp (Chief Financial Officer)



Numis Securities Limited
Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black (Joint Broker)



Stifel Nicolaus Europe Limited
Tel: +44 (0) 20 7710 7600
Jonathan Senior (Joint Broker)



FTI Consulting - for UK enquiries
Tel: +44 (0) 20 3727 1000
Simon Conway / Mo Noonan



MC Services AG - for Continental European enquiries
Tel: +49 (0) 211 52925222
Anne Hennecke

About Ergomed
Ergomed plc is a profitable UK-based business providing drug development services to the pharmaceutical industry and has a growing portfolio of co-development partnerships. It operates in over 50 countries. 
Ergomed provides clinical development, trial management and pharmacovigilance services to over 100 clients ranging from top 10 pharmaceutical companies to small and mid-sized drug development companies. Ergomed successfully manages clinical development from Phase I through to late phase programmes.
Ergomed has a wide therapeutic focus, with a particular expertise in oncology, neurology and immunology and the development of orphan drugs. Ergomed believes its approach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed and the physicians involved in clinical trials.
As well as providing high quality clinical development services, Ergomed is building a portfolio of co-development partnerships with pharma and biotech companies which share the risks and rewards of drug development. Ergomed leverages its expertise and services in return for carried interest in the drugs under development. Lastly, Ergomed recently acquired a pipeline of proprietary development products for haemostasis in surgical settings. For further information, visit: http://ergomedplc.com.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
DSHUROORNRAAOAA